Thursday, March 9, 2017

Dr Reddy's get 13 observations from USFDA

 Dr Reddy’s Laboratories has received received 13 observations from the USFDA for its Duvvada oncology formulation facility. 

The US FDA observations are a setback for Dr Reddy’s as it was expecting a clean chit from the US drug regulator inspection. The company didn’t specify the nature of these observations. The oncology formulation facility called Unit-7 is located in Visakhapatnam Special Economic Zone at Duvvada. 

The stock is likely to come under pressure in today's trade.

No comments:

Post a Comment